Statement: the outcome measures of the primary clinical trial and the secondary clinical trial are found to be identical
Primary_evidence: Outcome Measurement:    Safety of External-beam PBI Utilizing 40Gy in Ten Daily Fractions Over Two Weeks   The safety of external-beam PBI in selected stages 0 and I female breast cancer patients utilizing 40 Gy in ten daily fractions over two weeks. The study will be deemed too toxic if >10% of enrolled patients have at least one of the following outcomes within 24 months of completion of PBI.   Grade 3 or 4 skin/subcutaneous or pulmonary toxicity.   The development of clinical fat necrosis.   The development of rib fracture on the ipsilateral treated side, detected either clinically and/or radiographically.   The data is shown as the number of participants that experienced each of the specific toxicities.   Time frame: 2 years Results 1:    Arm/Group Title: Partial Breast Irradiation   Arm/Group Description: Partial Breast Irradiation using 40 Gy in 10 fractions over 2 weeks   External Beam Partial-Breast Irradiation: 40 Gy in ten daily fractions over two weeks   Overall Number of Participants Analyzed: 53   Measure Type: Count of Participants   Unit of Measure: Participants  Grade 3 or 4 Skin/ Subcutaneous toxicity: 0   0.0%   Grade 3 or 4 Pulmonary Toxicity: 0   0.0%   Fat Necrosis: 0   0.0%   Rib fractures on ipsilateral treated side: 0   0.0%
Secondary_evidence: Outcome Measurement:    Overall Tumor Response   Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment.   Time frame: every 3 cycles (approximately 6-7 weeks) or until patient has disease progression Results 1:    Arm/Group Title: Pemetrexed   Arm/Group Description: 600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression   Overall Number of Participants Analyzed: 35   Measure Type: Number   Unit of Measure: participants  Complete Response: 1   Partial Response: 8   Stable Disease: 14   Progressive Disease: 9   Best Response Not Evaluable: 3